These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 6994635)
41. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Gatermann S; Marre R Infection; 1991; 19(2):106-9. PubMed ID: 1646771 [TBL] [Abstract][Full Text] [Related]
42. Resistance of uropathogens in symptomatic urinary tract infections in León, Nicaragua. Matute AJ; Hak E; Schurink CA; McArthur A; Alonso E; Paniagua M; Van Asbeck E; Roskott AM; Froeling F; Rozenberg-Arska M; Hoepelman IM Int J Antimicrob Agents; 2004 May; 23(5):506-9. PubMed ID: 15120732 [TBL] [Abstract][Full Text] [Related]
43. Three-day and ten-day chemotherapy for urinary tract infections in general practice. Charlton CA; Crowther A; Davies JG; Dynes J; Haward MW; Mann PG; Rye S Br Med J; 1976 Jan; 1(6002):124-6. PubMed ID: 764915 [TBL] [Abstract][Full Text] [Related]
44. A comparison of the effects of ampicillin on Escherichia coli and proteus mirabilis. Greenwood D; O'Grady F J Med Microbiol; 1969 Nov; 2(4):435-41. PubMed ID: 4929795 [No Abstract] [Full Text] [Related]
45. Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions. Bergan T; Carlsen IB Infection; 1980; Suppl 1():103-8. PubMed ID: 6995345 [TBL] [Abstract][Full Text] [Related]
46. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates. Piccolomini R; Allocati N; Catamo G Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505 [TBL] [Abstract][Full Text] [Related]
47. Antibiotic treatment and antimicrobial resistance in children with urinary tract infections. Vazouras K; Velali K; Tassiou I; Anastasiou-Katsiardani A; Athanasopoulou K; Barbouni A; Jackson C; Folgori L; Zaoutis T; Basmaci R; Hsia Y J Glob Antimicrob Resist; 2020 Mar; 20():4-10. PubMed ID: 31252156 [TBL] [Abstract][Full Text] [Related]
48. Study of the enhancement of beta-lactam activity by amdinocillin in a model of the human urinary bladder. Anderson JD; Eftekhar F Am J Med; 1983 Aug; 75(2A):42-7. PubMed ID: 6311004 [TBL] [Abstract][Full Text] [Related]
49. In vitro activity against Escherichia coli of CGP 9000, a new oral cephalosporin. Greenwood D J Antibiot (Tokyo); 1978 Jul; 31(7):697-702. PubMed ID: 357363 [TBL] [Abstract][Full Text] [Related]
50. In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits. Fuchs PC; Barry AL; Thornsberry C; Gavan TL; Jones RN Antimicrob Agents Chemother; 1983 Jul; 24(1):31-8. PubMed ID: 6625554 [TBL] [Abstract][Full Text] [Related]
51. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections. Gisby J; Beale AS Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924 [TBL] [Abstract][Full Text] [Related]
52. [Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections]. Junquera S; Loza E; Baquero F Enferm Infecc Microbiol Clin; 2005 Apr; 23(4):197-201. PubMed ID: 15826543 [TBL] [Abstract][Full Text] [Related]
53. [Escherichia coli strains isolated from the urine of children with urinary tract infections and their antibiotic susceptibility. A comparative study from three centers]. Köksal I; Mocan H; Berkman E; Saltoğlu N Mikrobiyol Bul; 1990 Jul; 24(3):241-7. PubMed ID: 2283975 [TBL] [Abstract][Full Text] [Related]
54. [Etiological profile of urinary tract infections and antimicrobial susceptibility of urinary pathogens]. Eiros Bouza JM; Ochoa Sangrador C; An Pediatr (Barc); 2007 Nov; 67(5):461-8. PubMed ID: 17991366 [TBL] [Abstract][Full Text] [Related]
55. Prevalence of extrachromosomal drug resistance. R Factors in Escherichia coli. Datta N Ann N Y Acad Sci; 1971 Jun; 182():59-64. PubMed ID: 4936673 [No Abstract] [Full Text] [Related]
56. Comparative activity of mecillinam and ampicillin singly and in combination in the urinary bladder model and experimental mouse model. Anderson JD; Eftekhar F; Cleeland R; Kramer MJ; Beskid G J Antimicrob Chemother; 1981 Aug; 8(2):121-31. PubMed ID: 6268599 [No Abstract] [Full Text] [Related]
57. Principal beta-lactamases responsible for resistance to beta-lactam antibiotics in urinary tract infections. Simpson IN; Harper PB; O'Callaghan CH Antimicrob Agents Chemother; 1980 Jun; 17(6):929-36. PubMed ID: 6996612 [TBL] [Abstract][Full Text] [Related]
58. Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains. Matsuura M; Nakazawa H; Hashimoto T; Mitsuhashi S Antimicrob Agents Chemother; 1980 Jun; 17(6):908-11. PubMed ID: 6967713 [TBL] [Abstract][Full Text] [Related]
59. Comparative in vivo activity of bacampicillin and amoxycillin. Ekström B; Jalar LP; Magni L Infection; 1979; 7 Suppl 5():S438-42. PubMed ID: 389821 [TBL] [Abstract][Full Text] [Related]
60. Penicillin G or ampicillin for oral treatment of canine urinary tract infections. Ling GV; Gilmore CJ J Am Vet Med Assoc; 1977 Aug; 171(4):358-61. PubMed ID: 330479 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]